Abstract: This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline.

Abstract: The invention relates to methods for predicting a subject's response to antipsychotic drug treatment comprising the steps of obtaining a biological sample from the subject, and determining the presence or absence of one or more polymorphisms in the SLC1A1 gene of the subject, wherein the presence of the one or more polymorphisms indicates that the subject's response to antipsychotic drug treatment. The invention also provides for kits for performing these methods.

Abstract: The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG or GC genotype is at increased risk for tardive dyskinesia as compared to a subject comprising the GG genotype. Kits for practicing the method are also disclosed.

Abstract: The present invention provides methods for diagnosing or identifying susceptibility of a subject to an anxiety or mood disorder. One method involves testing a sample obtained from the subject for the presence of a polymorphism in Intron 10 of the SLC1A1 gene. The presence of allele G or allele A of the A/G polymorphism rs301434 indicates that the patient is susceptible to an anxiety disorder. An alternate method involves testing a sample obtained from the subject for the presence of a polymorphism in the 3? untranslated region of the SLC1A1 gene. The presence of allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to an anxiety disorder. Furthermore, a method is provided that involves testing a sample obtained from the subject for the presence of a haplotype in the SLC1A1 gene, wherein the combined presence allele G of the A/G polymorphism rs301434 and allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to a mood disorder.

Abstract: The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG or GC genotype is at increased risk for tardive dyskinesia as compared to a subject comprising the GG genotype. Kits for practicing the method are also disclosed.

Abstract: Methods and kits for determining susceptibility of a patient to mood disorders are described. The method involves analyzing a sample comprising nucleic acids from a patient for a polymorphism in the promoter region of the BDNF gene.

Abstract: Methods and kits for determining susceptibility of a patient to mood disorders are described. The method involves analyzing a sample comprising nucleic acids from a patient for a polymorphism in the promoter region of the BDNF gene.